P
US6962976B2ExpiredUtilityPatentIndex 49

Human TREK2, a stretch- and arachidonic acid-sensitive K+ channel activated by inhalational anesthetics and niluzole

Assignee: CENTRE NAT RECH SCIENTPriority: Jun 27, 2000Filed: Jun 27, 2001Granted: Nov 8, 2005
Est. expiryJun 27, 2020(expired)· nominal 20-yr term from priority
Inventors:LAZDUNSKI MICHELLESAGE FLORIANROMEY GEORGES
C07K 14/705A61P 23/00
49
PatentIndex Score
1
Cited by
10
References
4
Claims

Abstract

This invention relates to a protein including a mammalian K+ channel with two pore domains, designated TREK2, that produces currents whose current-voltage relationship is weakly inward rectifying in high symmetrical K+ conditions. This invention further relates to the isolation and characterization of such protein, as well as a method using TREK2 to identify bioactive compounds having anesthetic properties.

Claims

exact text as granted — not AI-modified
1. An isolated and purified protein comprising a mammalian K +  channel with two pore domains, wherein said channel produces currents whose current-voltage relationship is weakly inwardly rectifying in high symmetrical K +  conditions, and wherein said channel comprises the amino acid sequence of SEQ ID NO: 2. 
     
     
       2. The protein of  claim 1 , wherein said channel is a human K +  channel. 
     
     
       3. The protein of  claim 1  consisting essentially of the amino acid sequence of SEQ ID NO: 2. 
     
     
       4. The mammalian K +  channel of  claim 1 , wherein said high symmetrical K +  conditions is a K + -rich external medium of about 150 mM.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.